Metraipolis › archive › dc_49ef012a5ee7

Assessing the Early Economic Feasibility of a Curative Gene Therapy for Multiple Sclerosis Using a Risk-Adjusted Valuation Framework — Europe PMC PMID:41827627

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41827627
DOI
10.3390/healthcare14050674
License (as archived)
solo-consultazione
Archived
2026-11-05T01:07:23.502Z
SHA-256 of the archived text
8ea0a09147d514d751c480c7cf3acec615343a47b8c210c3ec99308aabbc835a
Stable URL of this page
https://metraipolis.com/documento/dc_49ef012a5ee7

How to cite

Assessing the Early Economic Feasibility of a Curative Gene Therapy for Multiple Sclerosis Using a Risk-Adjusted Valuation Framework — Europe PMC PMID:41827627 — Europe PMC (en), https://europepmc.org/article/MED/41827627 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_49ef012a5ee7 (Metraipolis archive dc_49ef012a5ee7, sha256 8ea0a09147d514d751c480c7cf3acec615343a47b8c210c3ec99308aabbc835a)
BibTeX
@misc{dc49ef012a5ee7,
  title = {Assessing the Early Economic Feasibility of a Curative Gene Therapy for Multiple Sclerosis Using a Risk-Adjusted Valuation Framework — Europe PMC PMID:41827627},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41827627},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_49ef012a5ee7; sha256 8ea0a09147d514d751c480c7cf3acec615343a47b8c210c3ec99308aabbc835a},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41827627. Agents can read the archived copy with the MCP tool read_document.